Integrum AB (publ) (INTEG_B) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's webcast with Integrum. We're acting CEO Scott Flora and CFO Jørgen Svalenström will present the Q3 report of 2024. After the presentation, there will be a Q&A. So if you have any questions to the company, you can send them in via the form to the right. And with that said, I hand over the word to you guys. Thank you, Ludvig, very much. And good morning, everybody. Good afternoon and real happy to be here and share our Q3 results and then talk about our path forward and answer a few questions that everybody may have. So with that, should we start the presentation? Sure. I don't think we can see the presentation yet. No. Great. Sorry, everybody. Okay. So just a reminder, uh, Integrum is a leading medical technology company. We've been, uh, we've been a pioneer in a bone anchored, um, prosthetic solutions for patients with amputations, uh, amputees for, uh, within Europe and the U S we, uh, uh, We've built a nice company. We've got results. We've updated our numbers now, 1,000 implants now. And we think we're in a really good position to accelerate growth in the U.S. market and then continue to grow nicely within the EU. But we're going to be very focused in those markets, as we'll talk about in a little bit. Next slide. Just a reminder that we are market positions within the U.S. and Europe. In the U.S., we have a PMA since 2020. We do operate a wholly owned subsidiary there. We have an internal sales force that focuses on the prosthetist. And then we use distribution independent orthopedic reps to call on the surgeons and the hospitals. And we figure the U.S. is worth about $5.6 billion to us in that TAM, given the number of patients that could use a bone anchor prosthetic solution. In the EU, we have CE marking since 1999. We have an inter...